A previous study described CD8+ lymphocyte levels as a prognostic biomarker in NSCLC [48], and specifically in lung adenocarcinoma [49], with a correlation between higher levels of CD8+ lymphocytes with higher survival rates and lower disease recurrence. This evidence concerns the gene CD8A and lung adenocarcinoma.